These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36323490)

  • 1. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
    Weitz JI; Szekanecz Z; Charles-Schoeman C; Vranic I; Sahin B; Paciga SA; Wang Z; Hyde C; Martin DA
    RMD Open; 2022 Nov; 8(2):. PubMed ID: 36323490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.
    Buch MH; Bhatt DL; Charles-Schoeman C; Giles JT; Mikuls T; Koch GG; Ytterberg S; Nagy E; Jo H; Kwok K; Connell CA; Masri KR; Yndestad A
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38609322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients.
    Charles-Schoeman C; Fleischmann R; Mysler E; Greenwald M; Ytterberg SR; Koch GG; Bhatt DL; Wang C; Mikuls TR; Chen AS; Connell CA; Woolcott JC; Menon S; Chen Y; Lee K; Szekanecz Z
    Arthritis Rheumatol; 2024 Aug; 76(8):1218-1229. PubMed ID: 38481002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.
    Balanescu AR; Citera G; Pascual-Ramos V; Bhatt DL; Connell CA; Gold D; Chen AS; Sawyerr G; Shapiro AB; Pope JE; Schulze-Koops H
    Ann Rheum Dis; 2022 Nov; 81(11):1491-1503. PubMed ID: 35922124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
    Curtis JR; Yamaoka K; Chen YH; Bhatt DL; Gunay LM; Sugiyama N; Connell CA; Wang C; Wu J; Menon S; Vranic I; Gómez-Reino JJ
    Ann Rheum Dis; 2023 Mar; 82(3):331-343. PubMed ID: 36600185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.
    Charles-Schoeman C; Buch MH; Dougados M; Bhatt DL; Giles JT; Ytterberg SR; Koch GG; Vranic I; Wu J; Wang C; Kwok K; Menon S; Rivas JL; Yndestad A; Connell CA; Szekanecz Z
    Ann Rheum Dis; 2023 Jan; 82(1):119-129. PubMed ID: 36137735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a
    Karpouzas GA; Szekanecz Z; Baecklund E; Mikuls TR; Bhatt DL; Wang C; Sawyerr GA; Chen Y; Menon S; Connell CA; Ytterberg SR; Mortezavi M
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231201047. PubMed ID: 37942277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
    Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
    Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Events, Malignancies, and Efficacy Outcomes in Latin American Patients With Rheumatoid Arthritis Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors: A Post Hoc Analysis of the ORAL Surveillance Study.
    Citera G; Mysler E; Kakehasi AM; Pascual-Ramos V; Masson W; Cadatal MJ; Rivas JL; Sheibanie F; Helling C; Ponce de Leon D
    J Clin Rheumatol; 2024 Aug; 30(5):208-216. PubMed ID: 38880956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
    Kristensen LE; Danese S; Yndestad A; Wang C; Nagy E; Modesto I; Rivas J; Benda B
    Ann Rheum Dis; 2023 Jul; 82(7):901-910. PubMed ID: 36931693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box.
    Misra DP; Pande G; Agarwal V
    Clin Rheumatol; 2023 Feb; 42(2):621-632. PubMed ID: 36264400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.
    Desai RJ; Pawar A; Weinblatt ME; Kim SC
    Arthritis Rheumatol; 2019 Jun; 71(6):892-900. PubMed ID: 30552833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
    Mori S; Ogata F; Tsunoda R
    Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
    Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
    Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
    Molander V; Bower H; Frisell T; Delcoigne B; Di Giuseppe D; Askling J;
    Ann Rheum Dis; 2023 Feb; 82(2):189-197. PubMed ID: 36150749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.
    Min HK; Kim H; Jeong HJ; Kim SH; Kim HR; Lee SH; Lee K; Shin SA; Park JH
    Epidemiol Health; 2023; 45():e2023045. PubMed ID: 37080728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.
    Khosrow-Khavar F; Kim SC; Lee H; Lee SB; Desai RJ
    Ann Rheum Dis; 2022 Jun; 81(6):798-804. PubMed ID: 35027405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
    Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
    Fleischmann R; Mysler E; Hall S; Kivitz AJ; Moots RJ; Luo Z; DeMasi R; Soma K; Zhang R; Takiya L; Tatulych S; Mojcik C; Krishnaswami S; Menon S; Smolen JS;
    Lancet; 2017 Jul; 390(10093):457-468. PubMed ID: 28629665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance.
    Batko B; Jeka S; Wiland P; Zielińska A; Stopińska-Polaszewska M; Stajszczyk M; Kosydar-Piechna M; Cadatal MJ; Rivas JL
    Rheumatol Ther; 2024 Oct; 11(5):1217-1235. PubMed ID: 39060905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.